Alphavirus RNA Replicon Vaccine for Passive Piglet Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional vaccines for swine influenza A virus (IAV-S) struggle to provide effective protection against diverse and rapidly evolving strains due to antigenic variability, leading to limited protection and the need for frequent updates, and existing strategies for passive immunity in piglets are inadequate for local mucosal pathogens like IAV-S.
Innovation Solution
A vaccine using an alphavirus RNA replicon particle (αRP) vector encoding IAV-S antigens is administered to pregnant female pigs, inducing both systemic and local immunity, which is then transferred to piglets through colostrum, providing protection against IAV-S and other pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional whole virus inactivated vaccines are used, then protection against IAV-S is provided, but protection is limited against diverse and emerging strains due to antigenic variability
Solution Approach 1:
The patent changes the fundamental parameter of the vaccine from whole virus inactivated to replicon particle-based, allowing the vaccine to target specific viral proteins (HA and NA) without requiring complete viral matching, thus maintaining effectiveness against diverse strains
Solution Approach 2:
The replicon particle vaccine platform can be designed to express multiple different viral proteins or antigens simultaneously, enabling a single vaccine formulation to provide broad protection against multiple IAV-S strains and subtypes, achieving multi-functionality in one product
2Reliability
If conventional vaccines are used, then IAV-S protection is attempted, but frequent updates are required to match circulating strains
Solution Approach 1:
The patent incorporates multiple antigen components into the vaccine formulation in advance, preparing the vaccine to recognize and respond to various emerging strains before they circulate, thereby reducing the need for frequent updates
3Reliability
If passive immunity strategies are used for piglets, then some protection is provided, but protection against local mucosal pathogens like IAV-S is inadequate
Solution Approach 1:
The patent incorporates mucosal adjuvants and delivery mechanisms that specifically target mucosal tissues (respiratory and gastrointestinal tracts), creating localized immune responses at the site of infection rather than relying solely on systemic immunity, thereby providing effective protection against mucosal pathogens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The αRP vector vaccine effectively induces high levels of protective antibodies in both female pigs and their piglets, reducing viral load and lung lesions, and offers broad protection against multiple IAV-S strains and other pathogens, enhancing lactogenic immunity.
Implementation Method 1
The invention concerns a swine influenza A viruses (IAV-S) vaccine that can be used for the passive immunization of progeny piglets by active immunization of female pigs
Implementation Method 2
passive immunization of piglets through ingestion of colostrum or milk from a female pig actively immunized with the vaccine
Data Source
AI summary
The present invention pertains to the use of a vaccine based on an alphavirus RNA replicon particle (αRP) vector encoding an antigen of an IAV-S for the passive vaccination of piglets against a pathogenic infection with swine influenza virus.